Personalized cancer vaccines

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

49 papers

Active filtersClassification:Supporting

Showing 1-12 of total 49 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026CrossrefSupporting evidence0 citations

First mRNA‑based flu vaccine wins US approval, Moderna’s Ebola candidate reaches the clinic, and early‑phase cancer vaccine trials broaden across personalized and off‑the‑shelf platforms

2026PubMedSupporting evidence

Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.

Crodel CC; Gork L; Göpel W; Linke P; Sinn K; Miethke J; Hochhaus A; Hilgendorf I

Jan 1, 2026Journal of cancer research and clinical oncology

2026PubMedSupporting evidence

Engineering smart polymeric lipid nanoparticles for breast cancer: The convergence of AI and medical personalization to enhance efficacy and safety.

Sayed U; Azamova D; Abdulqader AF; Kadhim AA; Jamuna KV; Singhal D; Tailor NK; Polatova D

Jan 1, 2026International journal of pharmaceutics

2026PubMedSupporting evidence

NR2C2 suppresses breast cancer progression and promotes T-Cell infiltration in the tumor microenvironment.

Li X; Yu X; Huang K; Luo S; Li J; Song C; Zhang J

Jan 1, 2026Journal of molecular histology

2026PubMedSupporting evidence

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies.

Dhillon S; Rathod H; Dhillon S

Jan 1, 2026Cureus

2026PubMedSupporting evidence

Targeting the Siglec/sialic-acid axis in glioblastoma: Glycome-mediated immune evasion and emerging therapeutic platforms.

Lee D; ElNemer W; Selim O; Patel P; Freeman S; Slika H; Ruchika F; Brem H; Jackson C; Tyler BM

Jan 1, 2026Neuro-oncology advances

2026PubMedSupporting evidence

The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.

Wang Y; Qi F; Zhang M; Wang Q; Liu Y; Lu B; Gao Y; Ren R; Hu M; Hu X; Nong J; Lin PP; Zhang T

Jan 1, 2026Cancer letters

2026PubMedSupporting evidence

Nanosystem-Mediated Intercellular Crosstalk Modulation in the Tumor Microenvironment for Enhanced Cancer Immunotherapy.

Zheng X; Xie Y; Wang Q; Yao T; He Y; Wang Y; Lin X; Li M

Jan 1, 2026Drug design, development and therapy

2026PubMedSupporting evidence

Ferroptosis in the Tumor Immune Microenvironment: Mechanisms, Nanomedicine, and Immunotherapy.

Sayed U; Rizaev J; Turaev R; Mamedova G; Badraldin SQ; Hassan YM; Tailor NK; Singh R

Jan 1, 2026Journal of cellular biochemistry

2026PubMedSupporting evidence

Biomaterial-based mitochondria-targeted nanomedicine for remodeling the breast cancer tumor microenvironment and overcoming therapy resistance.

Gu Y; Qu P; Li X; Shi J; Zhou M; Bai Z; Li G; Cheng P; Li X; Chen F; Liang Q

Jan 1, 2026Critical reviews in oncology/hematology

2026PubMedSupporting evidence

"Artificial Lighthouse" Overcomes Tumor Microenvironment Heterogeneity's "Sea Fog": Pre-Targeted Strategy-Mediated Nanomedicine Enables Tumor Body Fluid Detection, In Vivo Imaging, and Multitherapy Treatment.

Zhang Y; Sun Z; Wu D; Wang K; Song H; Li Y; Cao Y

Jan 1, 2026Macromolecular bioscience

2026PubMedSupporting evidence

Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.

Atoom AM; Rizaev J; Polatova D; Patel PN; Jamuna KV; Maharana L; Bainsal N; Singhal D

Jan 1, 2026Cancer treatment and research communications